EMA Authorised: Venclyxto (venetoclax) — AbbVie Deutschland GmbH & Co. KG

View source ↗

Summary

The European Medicines Agency authorised Venclyxto (venetoclax) for chronic lymphocytic leukemia (B-cell lineage) with AbbVie Deutschland as the marketing autho…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• Venclyxto (Venetoclax)

Snippet

Status: Authorised. Therapeutic area: Leukemia, Lymphocytic, Chronic, B-Cell. MAH: AbbVie Deutschland GmbH & Co. KG. Decision date: 21/10/2025